Elevated GFAP at 117 ng/mL Indicates Significant CNS Injury or Pathology
A GFAP level of 117 ng/mL (67% above the upper limit of 70 ng/mL) indicates active astrocytic injury or astrogliosis and requires immediate investigation for acute CNS pathology, particularly traumatic brain injury, acute ischemic stroke, or intracranial hemorrhage.
Clinical Significance of This Elevation
Your GFAP level is substantially elevated, which reflects one of the following pathological processes:
Most Urgent Considerations (Rule Out First)
Acute Ischemic Stroke: GFAP levels >0.18 ng/mL (180 pg/mL) are associated with severe neurological deficits (NIHSS >6), and levels >2.37 ng/mL predict severe deficits with 96.9% sensitivity 1. Your level of 117 ng/mL falls well within the pathological range and correlates with poor functional outcomes at 1 year 2
Traumatic Brain Injury: GFAP is almost exclusively expressed in astrocytes and has excellent accuracy in differentiating TBI patients from controls 3. Elevated GFAP improves TBI outcome prediction models and serves as a marker of intracranial injury 3, 4
Intracranial Hemorrhage: Persistent GFAP elevations can indicate ICH, a serious complication requiring urgent imaging 3
Other Diagnostic Possibilities
Neurodegenerative Disease: GFAP levels are significantly elevated in Alzheimer's disease (median 79.4 pg/mL vs 39.5 pg/mL in controls, with AUC = 0.86 for diagnosis) 5. Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies all causally increase plasma GFAP levels 6
Encephalitis: Genetically predicted higher GFAP levels are associated with increased encephalitis risk (OR = 2.52) 6
Glioblastoma: GFAP >0.05 μg/L (50 ng/mL) is 76% sensitive and 100% specific for glioblastoma multiforme in patients with single supratentorial mass lesions 7. Your level exceeds this threshold significantly
Immediate Action Required
Obtain urgent neuroimaging (CT or MRI brain) if not already done, as this GFAP elevation indicates active CNS pathology requiring diagnosis. The specific etiology cannot be determined by GFAP alone—it reflects astrocytic activation regardless of cause.
Clinical Context Matters
Timing: GFAP levels correlate with disease severity and timing. In stroke, levels measured at 24 hours and day 7 predict functional outcomes 8. In TBI, elevations persist and correlate with injury severity 3
Age adjustment: GFAP levels increase with normal aging, but your elevation is well beyond age-related changes 9
Systemic confounders: Unlike S100B (which is found in non-CNS tissues), GFAP is almost exclusively CNS-specific, though it can be found in testicular Leydig cells 3. This makes it a more reliable CNS biomarker
Prognostic Implications
The magnitude of your elevation suggests:
Poor functional outcome risk: In stroke patients, GFAP levels in the fourth quartile (highest) are associated with 70.4% poor outcome rate versus 12.7% in the first quartile 2
Mortality risk: In stroke, GFAP concentrations >0.25 ng/mL (250 pg/mL) measured within 24 hours show sharp increases in mortality 8
Disease severity: Strong positive correlation exists between GFAP levels and neurological deficit severity (r = 0.786) 1
Critical Pitfalls to Avoid
Do not dismiss as non-specific: While GFAP rises in multiple conditions, this level of elevation always indicates significant pathology requiring investigation
Do not delay imaging: GFAP cannot differentiate between stroke, TBI, tumor, or inflammation—imaging is mandatory
Consider hemolysis: Unlike NSE (which is sensitive to hemolysis), GFAP is relatively stable, but ensure the sample was properly handled 3